Back to discover

Protein / target

Large ribosomal subunit protein bL20

rplTQ9I0A2Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1)Swiss-Prot
UniProt: Q9I0A2NCBI Gene: 77220770
30
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Structural constituent of ribosome

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Binds directly to 23S ribosomal RNA and is necessary for the in vitro assembly process of the 50S ribosomal subunit.

View complete UniProt function annotation

Binds directly to 23S ribosomal RNA and is necessary for the in vitro assembly process of the 50S ribosomal subunit. It is not involved in the protein synthesizing functions of that subunit

Domains and Gene Ontology detail (5)

Gene Ontology

  • Ccytosolic large ribosomal subunit
  • FrRNA binding
  • Fstructural constituent of ribosome
  • Pribosomal large subunit assembly
  • Ptranslation

118 aa · 13 kDa

Approved medicines with mapped indications

1 medicine · 6 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Bacterial Infections1 medicine
tobramycin
Cystic Fibrosis1 medicine
tobramycin
Eye Infections1 medicine
tobramycin
Infections1 medicine
tobramycin
Inflammation1 medicine
tobramycin
Respiratory Tract Infections1 medicine
tobramycin

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

tobramycin
Inhibitor

70S ribosome inhibitor

Indicated for Bacterial Infections, Cystic Fibrosis, Eye Infections, Infections

Acts on a complex — shared with rpsJ, rpsK, rpsB +52 more · 1 of 56 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

Does Prophylactic Local Tobramycin Injection Lower Open Fracture Infection Rates?PHASE3

ACTIVE_NOT_RECRUITING · via tobramycin · NCT04964947

Acute Application Of Intrawound Antibiotic Powder In Open Extremity Fracture WoundsPHASE4

COMPLETED · via tobramycin · NCT04872400

Pilot Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection in Vascular Surgery PatientsPHASE4

UNKNOWN · via tobramycin · NCT03308253

IV Colistin for Pulmonary Exacerbations: Improving Safety and EfficacyPHASE4

COMPLETED · via tobramycin · NCT02918409

View all trials (26)
A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical ProstaglandinPHASE4

COMPLETED · via tobramycin · NCT02873806

A Randomized,Controlled Study to Evaluate the Efficacy,Indications,Adverse Reactions and Resistance of Combined Administration of Nebulized Tobramycin Compared With Systemic Administration Alone in Patients With BronchiectasisPHASE4

UNKNOWN · via tobramycin · NCT01677403

Tobramycin 300 mg o.d. Aerosol in in Adult Patients With Cystic Fibrosis: Pilot Study on Antimicrobial ActivityPHASE4

COMPLETED · via tobramycin · NCT01608555

What Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas AeruginosaPHASE4

UNKNOWN · via tobramycin · NCT01044719

Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric BlepharoconjunctivitisPHASE4

COMPLETED · via tobramycin · NCT00705159

Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.PHASE4

COMPLETED · via tobramycin · NCT01400750

Drug Elution Profile and Minimum Inhibitory Concentration of Antibiotic-loaded Cement After Primary Total Knee ArthroplastyPHASE3

COMPLETED · via tobramycin · NCT05429671

Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open FracturesPHASE3

TERMINATED · via tobramycin · NCT03705962

A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 YearsPHASE3

COMPLETED · via tobramycin · NCT01082367

A Single Arm 48-Week Follow-on Safety Study to the Core Study (A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa)PHASE3

COMPLETED · via tobramycin · NCT01111383

Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.PHASE3

COMPLETED · via tobramycin · NCT01155999

A Multicenter, Open Label, 2 Period Cross-over Study to Evaluate the PK of a 8 Week Continuous Treatment With 1x300mg/d and 2x300mg/d Tobramycin Inhaled With a 'Soft Mist' Nebulizer in Cystic Fibrosis (CF) SubjectsPHASE3

COMPLETED · via tobramycin · NCT00634192

A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% AzaSite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial ConjunctivitisPHASE3

COMPLETED · via tobramycin · NCT00105469

Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic FibrosisPHASE3

COMPLETED · via tobramycin · NCT00004829

Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin Via the Cyclops® in Children With Cystic FibrosisPHASE1/PHASE2

UNKNOWN · via tobramycin · NCT03485456

Topical Antibiotics in Chronic RhinosinusitisPHASE1/PHASE2

COMPLETED · via tobramycin · NCT03673956

Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective StudyPHASE1/PHASE2

COMPLETED · via tobramycin · NCT02269969

Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis BronchiectasisPHASE1/PHASE2

COMPLETED · via tobramycin · NCT02035488

Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaide® in Patients With Cystic Fibrosis.PHASE1/PHASE2

UNKNOWN · via tobramycin · NCT01337219

Nasal Inhalation of Tobramycin by the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization in the Upper AirwaysPHASE2

COMPLETED · via tobramycin · NCT00774072

Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis SessionPHASE1

COMPLETED · via tobramycin · NCT03904836

Pilot Study of the in Vivo Efficacy of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia ComplexPHASE1

COMPLETED · via tobramycin · NCT02212587

A Phase 1 Study in Healthy Volunteers Investigating the Delivery of Tobramycin Using the TobrAir® 6.0 Device Compared With the Delivery of Marketed Tobramycin Nebuliser Solution (TOBI®) by PARI LC® PLUS and PARI TurboBoy® SX and With Delivery of Tobramycin by the TOBI® Podhaler™ Device, Using Pharmacokinetic and Pharmacoscintigraphic Methods.PHASE1

COMPLETED · via tobramycin · NCT02207426

Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy SubjectsPHASE1

COMPLETED · via tobramycin · NCT01953367

A Phase 1, Single-Dose, Open-Label, Two-Way Crossover, Pharmacoscintigraphy Study of Aerosol Delivery Characteristics (Measured by In Vivo Lung Deposition, Nebulization Time, Serum Tobramycin Concentrations, and Pharmacokinetic Parameters) and Safety of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (No Compressor) vs. PARI LC PLUS (TM) Jet Nebulizer (With Compressor) in Healthy Subjects and in Subjects With Cystic FibrosisPHASE1

COMPLETED · via tobramycin · NCT00399945

Crossover Pharmacokinetic Study of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (no Compressor) vs. PARI LC PLUSTM Jet Nebulizer (With Compressor) in Cystic Fibrosis SubjectsPHASE1

COMPLETED · via tobramycin · NCT00420836

ClinicalTrials.gov via the drug-target graph.

What's happening now

8

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Label change2024-09-30

    Label change: TOBRAMYCIN (ANDA201422)

    fda · regulatory · fda · via tobramycin

  2. Label change2020-01-21

    Label change: TOBRAMYCIN (ANDA201422)

    fda · regulatory · fda · via tobramycin

  3. Label change2020-01-21

    Label change: TOBRAMYCIN (ANDA201422)

    fda · regulatory · fda · via tobramycin

  4. Label change2020-01-21

    Label change: TOBRAMYCIN (ANDA201422)

    fda · regulatory · fda · via tobramycin

  5. Regulatory approval2019-02-18

    Approval: Vantobra (previously Tobramycin PARI) (EMA)

    ema · regulatory · ema · via tobramycin

  6. New publication2017-03-03
    Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection.

    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2017 · 12 citations · Europe PMC · via tobramycin

  7. Regulatory approval2014-05-28

    Approval: TOBRAMYCIN (ANDA201422)

    fda · regulatory · fda · via tobramycin

  8. Regulatory approval2011-07-20

    Approval: Tobi Podhaler (EMA)

    ema · regulatory · ema · via tobramycin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.